Intract Pharma

We are delighted to announce that we've been awarded an @innovateuk grant to manufacture an oral antibody formulation using #Soteria in partnership with @ukCPI, @Pharmidex and @QuayPharma. Read more here: intractpharma.com/2018/11/09/int…

An innovative capsule could take the gold-standard treatment for #CrohnsDisease – infliximab – out of hospital and into patients’ homes for the first time. Find out about how this treatment can benefit Louise Barker from @ukCPI at: hubs.la/Q01bBVRk0 #WorldIBDDay

Scientist or Senior Scientist, Oral Protein Formulation job with Intract Pharma jobs.newscientist.com/en-gb/job/1401…

What will the future of healthcare look like? How will technology impact the way you manage your health? Chief Digital Officer at @sanofi shares his predictions 💡👨‍⚕️ euronews.com/next/2021/06/1…

April 22, 2021 | Featured Intract Pharma and NIBEC Enter into an Agreement to Develop a Novel Oral Peptide Therapy for Treatment of Ulcerative Colitis. intractpharma.com/2021/04/22/int…

April 01, 2021 | Featured Intract Pharma Enters into Research Collaboration with Ferring Pharmaceuticals to Evaluate Oral delivery of Monoclonal Antibodies for Treatment of Chronic Gastrointestinal Diseases

August 20, 2020 | Featured Intract Pharma Limited and Celltrion Group announce collaboration for development of oral Infliximab. intractpharma.com/2020/08/20/int…

May 26, 2020 | Featured Intract Pharma and N&S Pharmacy Investment announce partnership to develop orally-delivered GLP-1R agonist peptide therapeutic. intractpharma.com/2020/05/26/int…

May 05, 2020 | Featured Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics. intractpharma.com/2020/05/05/int…

October 24, 2019 | Featured Intract’s Soteria® and Phloral® Technologies Highlighted Among Revolutionary Approaches to Crack Oral Biologics Delivery Challenge intractpharma.com/2019/10/24/int…

May 07, 2019 | Phloral Carus Animal Health and Intract Pharma Enter Agreement to Develop Novel Drug Delivery Technology.

5th April 2019 London, UK and Tokyo, Japan: Intract Pharma Ltd and Neopharma Japan Co. Ltd, have announced entry into a collaboration to develop a novel therapeutic product for treatment of gastrointestinal diseases using Intract’s proprietary drug delivery technologies.

London, England, 27th March 2019. Intract Pharma has announced the launch of a first product incorporating its colon targeting technology, Phloral®. The product - called Yaldigo®/Asacol 1600 has been created and is marketed by Tillotts Pharma AG, Switzerland. @tillotts_pharma

Great talk by Vipul Yadav from @intractpharma on their innovative #Phloral and #Soteria oral drug delivery technologies for the delivery of antibodies! @APS_PharmSci #PharmSci2019

Our partners @intractpharma are working on some exciting drug delivery technologies including enabling biologics, like monoclonal antibodies, to be given as tablets rather than injectables. intractpharma.com/fomulation-tec…

Medication conundrums - @intractpharma are creating solutions to gut metabolism with innovative new oral drug delivery technology #veterinary #veterinarymedicine #vetinnovation #vetmed intractpharma.com

Intract has entered into an agreement with @carus_ah to develop new therapies for the Veterinary Market Read More here: intractpharma.com/2019/05/07/car… #AnimalHealth #Veterinarian

We are proud to announce that we've entered into a collaboration with @Neopharma1 to develop a novel treatment for #Gastrointestinal diseases. Read more here: intractpharma.com/2019/04/05/int…

Market launch of a first Phloral® coated product, read more here: intractpharma.com/2019/03/27/int…

Our colleagues @intractpharma , a spin out company from the @School_Pharmacy, have successfully been awarded over £1.4million in funding from @innovateuk to develop a scalable manufacturing process for novel oral antibody products. Read more: bit.ly/2THQ0iL

Head on over to intractpharma.com to see our new Phloral® and Soteria® videos!